Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

New Early Detection HCV Test Launched

Mediacom-Release-Ortho-Clinical-Diagnostics

Ortho-Clinical Diagnostics, Inc. Launches New Early Detection HCV Test

First Direct Detection Test for Hepatitis C Virus Core Antigen Now Available Outside the United States


RARITAN, N.J., Aug. 31 RNewswire-AsiaNet/ -- A new in vitro diagnostic assay, ORTHO(R) Antibody to HCV Core Antigen ELISA Test System, is now commercially available in countries outside of the United States. This is the first test to be commercialized for the direct detection of HCV core antigen, a marker of early infection in Hepatitis C infected individuals. Availability of this assay will reduce the worldwide transmission of HCV infection through infected blood.

HCV Ag Test System: Closing The Window For Hepatitis C Virus

International field studies with the ORTHO HCV core antigen assay demonstrate a significant performance improvement versus current immunoassay techniques in closing the HCV infectious window by 40-50 days. Performance data shared at the 1st Scientific Symposium on Technology for the Detection of Hepatitis C Virus Core Antigen held in Paris in March 2000 established the HCV Ag test as a viable option for the identification of HCV infectious blood donor units throughout the world.

"Implementing the HCV core antigen test to screen blood donations would significantly improve transfusion safety," said Anne-Marie Courouce, PhD, Head of the Unit of Virology at the National Institute of Blood Transfusion in Paris. Dr. Courouce presented data which showed the HCV Ag test detecting HCV infection approximately 49 days earlier than existing HCV antibody assays.

ORTHO HCV core antigen assay is also the only direct detection test system available today which provides results in under 3 hours, is compatible with existing equipment and is suitable for large-scale screening of individual blood donors. "We have worked diligently to bring ORTHO Antibody to HCV Core Antigen ELISA Test System to market because of its potential to improve the safety of the world's blood supply," states Gerard Vaillant, Ortho-Clinical Diagnostics, Company Group Chairman Diagnostics Worldwide. "This assay has helped us continue the tradition of delivering breakthrough assays in the field of hepatitis."

Worldwide Commercialization

Commercialization of the ORTHO HCV core antigen assay will include product registration worldwide. "We are actively involved in registration processes in key geographies around the globe and will continue to participate in studies to further our development of diagnostic applications and the next generation Ortho HCV core antigen blood screening test," said Bill Skillman, Vice President, Transfusion Medicine, Ortho-Clinical Diagnostics. The Ortho HCV core antigen assay is currently registered for use in France and Hungary and available for sale in Spain and Belgium.

The Investigational New Drug (IND) application for the United States filing was submitted to the U.S. Food and Drug Administration on August 30, 2000.

About Ortho-Clinical Diagnostics

Ortho-Clinical Diagnostics, a Johnson & Johnson company, is a leading provider of high-value diagnostic solutions for the global health-care community.

Committed to developing the most advanced tests for early detection or diagnosis of disease, the Company brings products to market that provide timely information and help to facilitate better medical decisions. Ortho-Clinical Diagnostics also provides blood screening and typing products that help to ensure the safety of the world's blood supply. In addition, through its patented dry slide and enhanced chemiluminescence technologies, the Company has transformed the way that clinical laboratories perform testing. Worldwide, health care professionals rely on Ortho-Clinical Diagnostics for innovative diagnostic solutions that promote effective diagnoses and enhance patient care.

(Note: ORTHO is a registered trademark of Ortho-Clinical Diagnostics, Inc.)

SOURCE: Ortho-Clinical Diagnostics, Inc.

CONTACT: Gayle S. Mestel of CCS R, Inc., 760-438-5250, or fax, 760-438-5230, gaylemccspr.com, for Ortho-Clinical Diagnostics, Inc.

ENDS

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Statistics New Zealand: COVID-19 Sees Record 12.2 Percent Fall In New Zealand’s Economy

Gross domestic product (GDP) fell by 12.2 percent in the June 2020 quarter, the largest quarterly fall recorded since the current series began in 1987, as the COVID-19 restrictions in place through the quarter impacted economic activity, Stats NZ said ... More>>

ALSO:

Climate: Scientists Release ‘Blueprint’ To Save Critical Ecosystems And Stabilize The Earth’s Climate

A group of scientists and experts produced the first comprehensive global-scale analysis of terrestrial areas essential for biodiversity and climate resilience, totaling 50.4% of the Earth's land. The report was published in Science Advances ... More>>

ALSO:

MPI: Independent Review Launched Into Assurances For Safe Transport Of Livestock By Sea

The Ministry for Primary Industries (MPI) has launched an independent review of the assurances it receives for the safe transport of livestock by sea. MPI Director-General Ray Smith says Mike Heron QC has been appointed to lead the review, which is expected ... More>>

ALSO:


Computers: New Zealand PC Market Grows Nearly 40% Due To Work From Home Demand

COVID-19 had large impacts on demand for PCs as businesses prepared for lockdowns by purchasing notebooks to mobilise their workforce. In the second quarter of 2020, New Zealand's Traditional PC market experienced a 39.7% year-on-year (YoY) growth ... More>>

ALSO:

Mediaworks: Reaches Agreement To Sell TV Operations To Discovery, Inc.

New Zealand’s largest independent commercial broadcaster MediaWorks and the global leader of real-life entertainment Discovery Inc. (“Discovery”) are pleased to announce they have reached a binding agreement regarding the sale of MediaWorks’ ... More>>

ALSO:

Ministry of Health: Public Transport Distancing Requirements Relaxed

Physical distancing requirements on public transport have been reviewed by the Ministry of Health to determine whether they are still required at Alert Level 2 (or below). The Ministry’s assessment is that mandatory face covering and individuals tracking ... More>>

ALSO:

NZHIA: New Zealand Hemp Industry Set To Generate $2 Billion Per Annum And Create 20,000 Jobs

A new report says a fully enabled hemp industry could generate $2 billion in income for New Zealand by 2030, while also creating thousands of new jobs. Written by industry strategist Dr Nick Marsh, the report has prompted calls from the New Zealand Hemp ... More>>

ALSO:

Stats NZ: One In 14 Employed People Report High Risk Of Losing Jobs

About one in 14 workers say they expect to lose their job or business by mid-2021, Stats NZ said today. A survey of employed people in the June 2020 quarter showed 7 percent felt there was a high or almost certain chance of losing their job or business ... More>>

ASB Quarterly Economic Forecast: NZ Economy Doing Better Than Expected, But Challenges Remain

August lockdown estimated to have shaved 8% off NZ’s weekly GDP, and 0.5% off annual GDP Economy now expected to shrink 5% (year-on-year) by end of 2020 Unemployment rate now expected to peak at 7.2% The latest ASB Quarterly Economic Forecast is less ... More>>

ALSO:

SAFE: Live Export Ship Carrying 5,800 New Zealand Cows Goes Missing In East China Sea

Livestock carrier Gulf Livestock 1 sent a distress signal at 4:45am NZT yesterday in the East China Sea. The area is affected by Typhoon Maysak. At 4pm a patrol plane spotted a lifeboat - with no people in it - and a man in lifejacket nearby. The ship ... More>>

ALSO:

FMA: Kiwisaver Fees Don't Match Performance

The Financial Markets Authority (FMA) today published an independent report into the passive and active investment management styles [i] used by KiwiSaver providers. The FMA commissioned MyFiduciary to test the extent that KiwiSaver providers were ... More>>